<h3>Background</h3> A substantial number of patients have symptomatic asthma despite treatment according to guidelines. Several studies have confirmed that tiotropium Respimat^®, a once-daily long-acting anticholinergic bronchodilator, improves lung function in symptomatic patients receiving at least medium-dose inhaled corticosteroids (ICS) + long-acting β₂-agonist (LABA) (Kerstjens <i>et al</i>. NEJM 2012;367:1198–207; Bateman <i>et al</i>. JACI 2011;128:315–22). Here we examine whether the atopic and/or allergic status of patients in these trials influenced their response to tiotropium Respimat^®. <h3>Method</h3> Two 48-week trials of tiotropium Respimat^® 5 µg (PrimoTinA-asthma^®: NCT00776984, NCT00772538) in patients (n = 912) on high-dose ICS + LABA; two 24-week trials of tiotropium Respimat^® 5 µg and 2.5 µg (MezzoTinA-asthma^®: NCT01172808, NCT01172821) in patients (n = 2100) on moderate-dose ICS. Pre-planned analyses (pooled populations) were performed in two subgroups defined at baseline as total serum immunoglobulin E (IgE) ≤ or &gt;430 μg/L or blood eosinophils ≤ or &gt;0.6×10⁹/L or clinical judgement of allergic status ('No' or 'Yes'). All tiotropium doses were delivered via the Respimat^® SoftMist™ inhaler. <h3>Results</h3> Tiotropium Respimat^® 5 µg or 2.5 µg improved peak and trough forced expiratory volume in 1 second versus placebo (Table) independent of IgE, eosinophil count and clinical judgement. <h3>Conclusion</h3> Once-daily tiotropium Respimat^® as add-on to ICS or ICS + LABA in patients with moderate to severe symptomatic asthma reduces airflow obstruction, apparently independent of their atopic and/or allergic status.